Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ)
Stock · NASDAQ · Health Care
$210.14as of 10/16/2026
Price chart
Active signals
JAZZ Signal Track Record
How signals performed across all stocks →What JAZZ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +0.7% | 53% | September 18, 2026 |
| Bollinger Band Breakdown | 18 | +2.8% | 61% | October 8, 2026 |
| Bollinger Band Breakout | 20 | +3.1% | 60% | July 7, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.1% | 46% | August 15, 2025 |
| Any 20-session window (baseline) | +0.8% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the trea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2,890
- Website
- www.jazzpharma.com/
Fundamentals
- 1-day range
- $212.19$217.52
- Market cap
- $16.66B
- P/E (trailing)
- 14.90
- P/E (forward)
- 8.23
- EPS (trailing)
- $14.63
- Dividend yield
- —
- Beta
- 0.37
- Avg. volume
- 880.5K
How Jazz Pharmaceuticals plc Common Stock (Ireland) Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Jazz Pharmaceuticals plc Common Stock (Ireland) Competitors
Chosen by industry and closest market cap.
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$210.23▼ 1.95%Market cap $16.66BP/E 14.90$128.8$266.38
- BBIOBridgeBio Pharma Inc. Common Stock$66.39▼ 1.10%Market cap $16.20BP/E —$52.75$93.42
- ASNDAscendis Pharma A/S Ordinary Share$225.25▼ 0.60%Market cap $15.49BP/E 16.93$186.05$282.15
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 14.90 | $210.23 | ▼ 1.95% | $128.8$266.38 |
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $66.39 | ▼ 1.10% | $52.75$93.42 |
| ASND Ascendis Pharma A/S Ordinary Share | $15.49B | 16.93 | $225.25 | ▼ 0.60% | $186.05$282.15 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value StockChartMill · 10/9/2026
- RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296benzinga · 10/8/2026
- RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296Benzinga · 10/8/2026
- Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286Benzinga · 10/7/2026
- CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough SummitYahoo · 10/6/2026
- Cannabis Stocks Aren’t a Recovery Trade: Narrow Leadership Splits Quality and MomentumChartMill · 10/6/2026
- Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals StocksYahoo · 9/30/2026
- Target upgraded, Moderna downgraded: Wall Street's top analyst callsYahoo · 9/30/2026
- Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin DriverSeekingAlpha · 9/26/2026
Insider Activity
Insider Actions →- Renee D. Gala · October 6, 2026 · Sale2.0K @ $236.4
- Bruce C. Cozadd · October 1, 2026 · Sale6.0K @ $230.33
- Neena M. Patil · September 10, 2026 · Sale1.2K @ $240.94
- Mary Elizabeth Henderson · September 8, 2026 · Tax Withholding15 @ $241.2
- Mary Elizabeth Henderson · September 8, 2026 · Tax Withholding1.4K @ $243.03
- Renee D. Gala · September 8, 2026 · Sale2.0K @ $243.03
- Renee D. Gala · September 8, 2026 · Tax Withholding2.0K @ $246.81
- Bruce C. Cozadd · September 1, 2026 · Sale6.0K @ $250.13
- Patrick Kennedy · August 31, 2026 · Tax Withholding1.8K @ $241.39
- Patrick Kennedy · August 31, 2026 · Tax Withholding15 @ $244.06
- Mary Elizabeth Henderson · August 31, 2026 · Tax Withholding16 @ $244.64
- Mary Elizabeth Henderson · August 31, 2026 · Tax Withholding2.1K @ $241.39
- Mark Douglas Smith · August 31, 2026 · Tax Withholding1.7K @ $241.39
- Mark Douglas Smith · August 31, 2026 · Tax Withholding14 @ $244.64
- Jennifer E. Cook · August 31, 2026 · Tax Withholding1.7K @ $241.39
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.